Nine pharmaceutical companies such as JW Therapeutics, Fosun Kite, Carsgen Therapeutics, HRAIN Biotechnology, Genor Biopharma and others have officially established the Shanghai Alliance for Immune Cell Therapy Industry. The Shanghai Biomedicine Science and Technology...
I-MAB, a Shanghai-based startup has agreed with MorphoSys on the exclusive development and commercialization of MOR202 in China, Taiwan, Hong Kong and Macau. The investigational drug MOR202 is a human HuCAL antibody directed against the CD38 target. Scientifically...
A biomedical engineer by education, Tao XU is presently Director of the Innovation Center of Instruments and Technologies for Life Sciences at CAS Beijing Institute of Life Sciences. His focus is on membrane and vesicle transport. Born in May 1970, he was a postdoc...
On average, there were 4 IPO per month, and nearly 90 % of the companies had VC/PE support. The original investment period of 8-10 years was reduced to about 3-5 years. Total funds raised reached over 200 billion yuan. China Bio news release, November 30,...
Cyanobacteria such as Synechococcus sp. PCC 7942 overproduce sucrose to achieve osmotolerance in saline solution. The teams around Xuefeng LU and Quan LUO at CAS Qingdao Institute of Bioenergy and Bioprocess Technology (QIBEBT), in collaboration with Martin Hagemann...
According to a CFDA law amendment brought to congress vote, certification of drugs in China might be simplified in the future: 1. permission for manufacture and GMP certificate will be combined in one certificate, and 2. permission for storage (GSP = good storage...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
